These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30504527)

  • 1. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.
    Mori H; Suzuki H
    J Neurogastroenterol Motil; 2019 Jan; 25(1):6-14. PubMed ID: 30504527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
    Simadibrata DM; Syam AF; Lee YY
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
    Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
    Echizen H
    Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without
    Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M
    Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.
    Shirai Y; Kawami N; Iwakiri K; Kuwana M
    J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test.
    Masaoka T; Kameyama H; Yamane T; Yamamoto Y; Takeuchi H; Suzuki H; Kitagawa Y; Kanai T
    J Neurogastroenterol Motil; 2018 Oct; 24(4):577-583. PubMed ID: 30347936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
    Pilotto A; Franceschi M; Longoa MG; Scarcelli C; Orsitto G; Perri FC; D'Ambrosio LP; Leandro G
    Dig Liver Dis; 2004 Oct; 36(10):666-70. PubMed ID: 15506665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Benefits of Vonoprazan as
    Miftahussurur M; Pratama Putra B; Yamaoka Y
    Pharmaceuticals (Basel); 2020 Sep; 13(10):. PubMed ID: 32998241
    [No Abstract]   [Full Text] [Related]  

  • 12. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vonoprazan-based therapy for
    Akazawa Y; Fukuda D; Fukuda Y
    Therap Adv Gastroenterol; 2016 Nov; 9(6):845-852. PubMed ID: 27803739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers].
    Choi YJ
    Korean J Gastroenterol; 2022 Dec; 80(6):247-253. PubMed ID: 36567437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
    Sugano K
    Therap Adv Gastroenterol; 2018; 11():1756283X17745776. PubMed ID: 29383028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
    Graham DY
    Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicobacter pylori and Nonmalignant Diseases.
    Potamitis GS; Axon AT
    Helicobacter; 2015 Sep; 20 Suppl 1():26-9. PubMed ID: 26372821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New trends of acid-related diseases treatment].
    Koike T; Nakagawa K; Kanno T; Iijima K; Shimosegawa T
    Nihon Rinsho; 2015 Jul; 73(7):1136-46. PubMed ID: 26165070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.
    Oshima T; Miwa H
    J Neurogastroenterol Motil; 2018 Jul; 24(3):334-344. PubMed ID: 29739175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.